Epstein Secrets

n-adviser-ron-klain-trump-stonewalling-harming/> EFTA00137221 (11/15, 492K), which reports Klain "said Mr. Biden's team will begin consulting with Pfizer and other vaccine makers this week but they would like to be able to speak with key officials involved in the vaccine rollout, calling it a `giant

r to release an early analysis of vaccine trial data," could apply for the FDA's emergency authorization "as early as this week." BioNTech CEO Ugur Sahin: "If everything continues to go well, we will start to deliver the vaccine end of this year, beginning next year." However, Lopez added, "Supplying

ition" provides similar coverage, as does the Washington Times (11/15, 492K), which reports Klain "said Mr. Biden's team will begin consulting with Pfizer and other vaccine makers this week but they would like to be able to speak with key officials involved in the vaccine rollout, calling it a `giant

health measures such as social distancing and wearing masks will still need to be maintained even once you get a vaccine." The AP (11/15) reports Sahin said, "Our goal is to deliver more than 300 million of vaccine doses until April next year, which could allow us to already start to make an impact.

ition" provides similar coverage, as does the Washington Times (11/15, 492K), which reports Klain "said Mr. Biden's team will begin consulting with Pfizer and other vaccine makers this week but they would like to be able to speak with key officials involved in the vaccine rollout, calling it a `giant

health measures such as social distancing and wearing masks will still need to be maintained even once you get a vaccine." The AP (11/15) reports Sahin said, "Our goal is to deliver more than 300 million of vaccine doses until April next year, which could allow us to already start to make an impact.

h the call Ugur Sahin, chief executive of the German medical start-up BioNTech, had been anxiously EFTA00162637 awaiting. `Are you sitting down?' Pfizer chief Albert Bourla asked him. The news that followed was better than Sahin had hoped: Preliminary analysis from Phase 3 trials of his company's co

h, had been anxiously EFTA00162637 awaiting. `Are you sitting down?' Pfizer chief Albert Bourla asked him. The news that followed was better than Sahin had hoped: Preliminary analysis from Phase 3 trials of his company's coronavirus vaccine showed go percent protection," Loveday Morris reports from

ition" provides similar coverage, as does the Washington Times (11/15, 492K), which reports Klain "said Mr. Biden's team will begin consulting with Pfizer and other vaccine makers this week but they would like to be able to speak with key officials involved in the vaccine rollout, calling it a `giant

s such as social distancing and wearing masks will still need to be maintained even once you get a vaccine." EFTA01658929 The AP (11/15) reports Sahin said, "Our goal is to deliver more than 300 million of vaccine doses until April next year, which could allow us to already start to make an impact.